山东医药2011，Vol.51Issue(6)：20-22,3.
TAC、TEC方案新辅助化疗治疗乳腺癌效果比效
Comparison of neoadjuvant chemotherapy effect between regimen TAC and TEC in patients with breast cancer
摘要
Abstract
Objective To compare the clinical efficacy of TAC and TEC as the neoadjuvant chemotherapy regimens in the treatment of breast cancer.Methods 139 cases of breast cancer patients were collected and randomly divided into TAC group (71 cases) and TEC group(68 cases).The two groups were received TAC(docetaxel + pirarubicin + cyclophosphamide) or TEC (docetaxel + epirubicin + cyclophosphamide) regimen as neosdjuvant chemotherapy respectively.Clinical responses and side effects were assessed after neoadjuvant chemotherapy 4～6 cycles.Results The overall response rate (RR), pathologic complete remission (pCR), clinical complete remission(cCR), clinical partial remission(cPR), stable disease (SD)of group TAC respectively were 88.7％ 、11.3％ 、28.2％ 、60.6％ and 11.3％.TEC group respectively were 86.8％ 、10.3％ 、26.5％ 、60.3％ and 13.2％.There was no difference between the two groups(P ＞0.05).In side effects,including leukopenia, thrombocytopenia,constipation, cardiotoxity ,abnormality and hepatorenal dysfunction, there was also no significant difference ( P ＞0.05).Only the gastroenteric reaction including nausea and voniting,the TAC group(46.5％ ) lower to TEC group(66.2％ ) (P＜0.05).All patients received operation after neoadjuvant chemotherapy.Conclusions TAC and TEC regimen treated breast cancer are both effective and have little side effects.Pirarubicin as well as epirubicin can be ueed conventional in neoadjuvant chemotherapy of breast cancer.关键词
乳腺肿瘤/吡柔比星/表柔比星/药物疗法/新辅助化疗分类
医药卫生引用本文复制引用
臧梦芳,只向成,张敏,谷峰..TAC、TEC方案新辅助化疗治疗乳腺癌效果比效[J].山东医药,2011,51(6):20-22,3.基金项目
国家自然科学基金资助项目(30800355). （30800355）
